Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  TB-500: What the Research Actually Says About This Peptide

TB-500: What the Research Actually Says About This Peptide

Jun 11, 2026 4 min Healing & Recovery
TL;DR
TB-500 is a small synthetic fragment derived from a naturally occurring protein called thymosin β4. Preclinical studies in animals suggest it may support wound healing and tissue repair, but no human clinical trials have confirmed these effects. It remains an unapproved, research-only compound and is banned in competitive sports.

What Is TB-500?

TB-500 is a short synthetic peptide — basically a tiny chain of amino acids. Its full chemical name is Ac-LKKTETQ, and it is designed to mimic a specific active region of a naturally occurring protein called thymosin β4 (Tβ4).[5]

Think of thymosin β4 as a large key. TB-500 is a small copy of just the part of that key that does the most work. That active region is responsible for actin binding (actin is a structural protein inside cells), cell migration, and wound healing.[5]

Researchers first needed ways to detect it in biological samples — leading to studies on how it behaves in the body and how long it can be found after use.[3]

What Is Research Studying TB-500 For?

Scientists are primarily investigating TB-500 in the context of tissue repair and recovery. Here are the main areas:

  • Wound healing: Lab studies suggest TB-500 and its breakdown products (metabolites) may help skin fibroblasts — the cells that repair wounds — close injuries faster.[3]
  • Angiogenesis: That's the process of growing new blood vessels. Better blood supply helps injured tissue recover. TB-500 has been studied for its potential to promote this process in skin and connective tissue.[5]
  • Musculoskeletal injuries: Sports medicine researchers are interested in whether TB-500 could help tendons, muscles, and other soft tissues heal after injury.[2]
  • Inflammation reduction: Some preclinical work suggests it may help dial down the inflammatory response after injury.[1]

What Does the Evidence Actually Show?

Here is where it gets important to be honest. Most of the evidence comes from animal studies and lab experiments — not human clinical trials.

A 2024 study mapped out exactly how TB-500 breaks down in the body. It found that the parent peptide itself may not be the active ingredient. Instead, a specific metabolite called Ac-LKKTE showed significant wound-healing activity in fibroblast cells, while the original TB-500 molecule did not show the same effect on its own.[3] This is a meaningful finding — it means researchers are still working out which form of the compound does what.

A 2026 review published in The American Journal of Sports Medicine looked at the evidence specifically for orthopaedic use. It confirmed that TB-4 and its derivative TB-500 have shown promise promoting angiogenesis and tissue repair in preclinical (animal) models, but stated plainly that human orthopaedic data are lacking.[2]

Another 2026 review in Sports Medicine echoed this conclusion: many unapproved peptides, including TB-500, show favorable results in animal models, but rigorous human safety data are scarce, and there is potential for harm.[4]

A separate orthopaedic review noted that TB-500 works on key molecular pathways — including those controlling inflammation, tissue remodeling, and blood vessel growth — but stressed that clinical trials in humans are currently lacking.[1]

Regulatory Status and Sports Rules

TB-500 is not approved by the FDA or equivalent agencies for human use. It is classified as a research compound only.

In competitive sports, it is a banned substance. Anti-doping laboratories have developed specific testing methods to detect it in urine and plasma samples — methods originally developed for equine (horse) sports, where its misuse was first flagged.[5] Its behavior in anti-doping tests has also been studied to understand how it interacts with collection equipment, which matters for accurate detection.[6]

Where Does TB-500 Research Go From Here?

Researchers are optimistic but cautious. The mechanistic clues from animal and lab studies are genuinely interesting — the pathways involved in wound healing, inflammation, and tissue remodeling are real and relevant. The 2024 metabolite study in particular opens a new question: should future research focus on Ac-LKKTE rather than TB-500 itself?[3]

For now, scientists agree that well-designed human clinical trials are the essential next step before anyone can draw conclusions about safety or effectiveness in people.[2][4]

Research Dosage Reference

Because TB-500 is studied across a range of experimental models, dosing protocols in the literature vary widely. If you are a researcher looking for a structured reference, the TB-500 dosage chart compiles published protocols in one place. You can also use the calculator to cross-reference weight-based values used in preclinical studies. These tools are for research and educational reference only — not medical advice.

Sources

  1. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026. PMID 41490200.
  2. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026. PMID 41476424.
  3. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. — Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024. PMID 38382158.
  4. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.), 2026. PMID 41966639.
  5. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. — Journal of chromatography. A, 2012. PMID 23084823.
  6. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. — Analytical biochemistry, 2017. PMID 28887173.
See the dosage chart — TB-500
A synthetic fragment of Thymosin Beta-4 researched for cell migration, angiogenesis and re
TB-500

FAQ

What is TB-500 made from?
TB-500 is a synthetic peptide — a short, lab-made chain of amino acids. Its sequence (Ac-LKKTETQ) is copied from a specific active region of thymosin β4, a naturally occurring protein found in many human and animal tissues. The N-terminus is artificially acetylated, meaning a small chemical group is added to one end to stabilize the molecule.[5]
Has TB-500 been tested in humans?
Not in any published clinical trials for orthopaedic or sports medicine use. Multiple 2026 reviews confirm that the existing evidence comes almost entirely from animal models and lab experiments. Researchers agree that human trials are the critical missing piece before any clinical recommendations could be made.[2][4]
Is TB-500 the same as thymosin β4?
No — TB-500 is a fragment of thymosin β4, not the full protein. It is a much smaller synthetic peptide that replicates just the actin-binding active site of the larger protein. Research suggests the two may behave differently in the body, and even TB-500's own metabolites appear to have distinct biological effects compared to the parent compound.[3][5]
Why is TB-500 banned in sports?
TB-500 is on the World Anti-Doping Agency (WADA) prohibited list because of its potential to enhance recovery and performance — specifically through angiogenesis and tissue repair pathways. Anti-doping labs have developed detection methods for it in urine and plasma, first validated in equine sports testing.[5] It is also unapproved for human use, adding a safety concern on top of the fairness issue.
For research and educational use only. Not medical advice.